Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(13):930-931; doi:10.1093/jnci/95.13.930
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Albertsen, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albertsen, P. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 13, 930-931, July 2, 2003
© 2003 Oxford University Press

EDITORIAL

The Prostate Cancer Conundrum

Peter C. Albertsen

Correspondence to: Peter C. Albertsen, M.D., University of Connecticut School of Medicine, Department of Surgery, Farmington, CT 06030-3955 (e-mail: Albertsen@NSO.UCHC.EDU).

The first 10% of the full text of this article appears below.

In 2003, the American Cancer Society estimates that 220 900 men will be diagnosed with prostate cancer and that 28 900 will die from this disease (1). Since the introduction of testing for prostate-specific antigen (PSA), the incidence of prostate cancer has increased, whereas the mortality from this disease has decreased. During the early 1990s, mortality from prostate cancer peaked in the United States at a rate of 26.4 prostate cancer deaths per 100 000 men at risk. By 1998, this rate had fallen to 21.5 per 100 000 men at risk, a decline of 2.6% per year (2). The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. D. Fesinmeyer, R. Gulati, S. Zeliadt, N. Weiss, A. R. Kristal, and R. Etzioni
Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States
Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
P. A. Shaw, R. Etzioni, S. B. Zeliadt, A. Mariotto, K. Karnofski, D. F. Penson, N. S. Weiss, and E. J. Feuer
An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States
Am. J. Epidemiol., December 1, 2004; 160(11): 1059 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Akaza, M. Usami, S. Hinotsu, O. Ogawa, S. Kagawa, T. Kitamura, T. Tsukamoto, S. Naito, Y. Hirao, M. Murai, et al.
Characteristics of Patients with Prostate Cancer Who Have Initially been Treated by Hormone Therapy in Japan: J-CaP Surveillance
Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 329 - 336.
[Abstract] [Full Text] [PDF]